Read by QxMD icon Read

Bioidentical hormone replacement therapy

James M Whedon, Anupama KizhakkeVeettil, Nancy A Rugo, Kelly A Kieffer
BACKGROUND: Proponents of bioidentical estrogens claim that they are superior for treating menopausal symptoms, including depressive symptoms. Small trials examining the effects of bioidentical estrogens on depressive symptoms show conflicting results. We conducted a systematic review to assess the effectiveness and safety of bioidentical estrogens for treatment of depressive symptoms in peri- and postmenopausal women. METHODS: We searched the scientific literature for randomized controlled trials of at least 4 weeks duration, comparing bioidentical estrogen with placebo for depressive symptoms in menopausal women...
January 2017: Journal of Women's Health
Joao Correia De Pinho, Lusine Aghajanova, Christopher N Herndon
BACKGROUND: Gynecomastia is a disorder of the endocrine system characterized by an abnormal presence of a palpable unilateral or bilateral enlargement and proliferation of glandular ductal benign breast tissue in male individuals. This case discusses the medical implications of an unregulated, indirect exposure to nonformulary, bioidentical hormone replacement therapy in male children. CASE: An 8-year-old boy presented with prepubertal gynecomastia secondary to estrogen exposure from maternal use of bioidentical hormonal replacement therapy (the Wiley protocol)...
January 2016: Journal of Reproductive Medicine
James V Hennessey
OBJECTIVE: To describe the history, refinements, implementation, physiology, and clinical outcomes achieved over the past several centuries of thyroid hormone replacement strategies. METHODS: A Medline search was initiated using the following search terms: bioidentical thyroid hormone, thyroid hormone extract, combination thyroxine (T4) and tri-iodothyronine (T3) therapy, homeopathic thyroid hormone therapy, and thyroid hormone replacement. Pertinent articles of interest were identified by title (and where available abstract) for further review...
October 2015: Endocrine Practice
Vrabic L Dezman, M Z Gersak, K Gersak
No abstract text is available yet for this article.
May 2015: International Journal of Gynecological Cancer
Sinan Guven, Jennifer S Lindsey, Ishwari Poudel, Sireesha Chinthala, Michael D Nickerson, Behzad Gerami-Naini, Umut A Gurkan, Raymond M Anchan, Utkan Demirci
Hormone replacement therapies have become important for treating diseases such as premature ovarian failure or menopausal complications. The clinical use of bioidentical hormones might significantly reduce some of the potential risks reportedly associated with the use of synthetic hormones. In the present study, we demonstrate the utility and advantage of a microfluidic chip culture system to enhance the development of personalized, on-demand, treatment modules using embryoid bodies (EBs). Functional EBs cultured on microfluidic chips represent a platform for personalized, patient-specific treatment cassettes that can be cryopreserved until required for treatment...
March 2015: Stem Cells Translational Medicine
Hannelore Rott
Many large trials in the past 15 years have proven an increased risk of vascular complications in women using oral, mostly non-bioidentical, hormone therapy. The risk of vascular complications depends on the route of administration (oral versus transdermal), age, duration of administration, and type of hormones (bioidentical versus non-bioidentical). Acquired and/or hereditary thrombophilias (eg, factor V Leiden, prothrombin mutation G20210A, and others) lead to a further increase of risk for venous thromboembolism, stroke, or myocardial infarction...
2014: International Journal of General Medicine
Andres D Ruiz, Kelly R Daniels
Prior studies demonstrated improved menopausal symptom relief following treatment with compounded bioidentical hormone replacement therapy; however, clinical effectiveness studies evaluating different routes of bioidentical hormone replacement therapy administration are lacking. The objective of this study was to determine the effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy for the treatment of vasomotor, mood, and other quality-of-life symptoms in post-menopausal women...
January 2014: International Journal of Pharmaceutical Compounding
T S Wiley, R D Odegard, J Raden, J T Haraldsen
Sterile and nonsterile compounding of medication has attracted much attention over the last few years due to the onset of various infections and negative compounding practices. This paper reports on the standardization of compounded hormones utilizing the Wiley Protocol, which provides nonsynthetic bioidentical estradiol, progesterone, dehydroepiandrosterone, and testosterone in a transdermal topical cream base for women and men in a standardized dosing regimen. Here, we present data from 2008 through 2012, which details the process of standardization and quality testing of the hormones through submission of random compounded samples for quality control and assessment...
March 2014: International Journal of Pharmaceutical Compounding
Scott T Wepfer
No abstract text is available yet for this article.
March 2002: International Journal of Pharmaceutical Compounding
Scott T Wepfer
No abstract text is available yet for this article.
January 2002: International Journal of Pharmaceutical Compounding
Filippo Santoro
No abstract text is available yet for this article.
September 2002: International Journal of Pharmaceutical Compounding
Narisa Y Holt-Waldo, Kenna Stephenson
The qualitative study described in this article includes excerpts from the thesis of NaRisa Y. Holt-Waldo, MSN,RN. Research on the lived experience of women undergoing treatemnt with bioidentical human hormone replacement therapy for the relief of perimenopausal or menopausal symptoms was conducted in the College of Nursing at the University of Texas at Tyler, Texas. Implications of the study results for the fields of nursing and pharmacy are also presented.
July 2007: International Journal of Pharmaceutical Compounding
Jim Paoletti
There are many misconceptions about the profession of pharmaceutical compounding and the preparation of bioidentical hormones used in hormone replacement therapy. These misconceptions are unfounded, because compounding is regulated by individual state boards of pharmacy, and compounded bioidentical hormones are prepared only when prescribed by a physician who has made a professional judgment in the interest of the patient. Physicians and the pharmacists who compound bioidentical hormones have not only the right but also the responsibility to be aware of current information published in the scientific literature concerning any prescribed medication...
July 2007: International Journal of Pharmaceutical Compounding
Fei-Shu Hu, Dana Reed-Kane, Jolaine R Draugalis
The purpose of this study was to assess whether the satisfaction of women who took part in the pharmacist-administered bioidentical hormone replacement therapy consultation service at an urban compounding pharmacy has improved since implementation of a follow-up call program. A questionnaire was mailed to 200 randomly selected women who completed hormone replacement therapy consultation and received all three follow-up calls from the pharmacy during the period from July 22, 2003, to April 22, 2004. The returned surveys were tabulated and analyzed, and independent t-tests were used to compare data collected in 2001 with that collected in 2004 on questionnaire items of interest...
May 2006: International Journal of Pharmaceutical Compounding
Joseph J Collins, Marla Ahlgrimm
The opinion paper titled "Compounded Bioidentical Hormones," published by the American College of Obstetricians and Gynecologists in November 2005, appears to be aimed at influencing how some clinicians care for their patients. The paper may not accurately report the findings of authors listed in its own references in regard to safety and efficacy of bioidentical hormones, nor does it address the fact that a number of mass-produced preparations on the market include bioidentical estadiol, progesterone, and/or testosterone...
March 2008: International Journal of Pharmaceutical Compounding
Bethany L Bramwell
This article reviews a collection of recent articles and published studies on sex hormone replacement therapy with the use of endogenous human hormones including estradiol, estriol, progesterone, and testosterone.
September 2010: International Journal of Pharmaceutical Compounding
Doris Moro, Wendy Young, Richard Stein, Winston Isaac, Deborah Goodman
The objective of this exploratory qualitative study was to describe (1) the key factors affecting women's initial decision to explore the use of bioidentical hormone, (2) where women gather their information on bioidentical hormones, (3) the enablers and barriers to obtaining bioidentical hormones, and (4) how to improve the bioidentical hormone replacement therapy access path. The study was conducted in a compounding pharmacy located in a large urban area in southern Ontario, Canada. The participants included four postmenopausal women between the ages of 46 and 72 who self-identified as users of bioidentical hormone replacement therapy and with comprehensive provincial healthcare coverage...
March 2010: International Journal of Pharmaceutical Compounding
Irene White
No abstract text is available yet for this article.
July 2005: International Journal of Pharmaceutical Compounding
Kristy A Vigesaa, Nathan P Downhour, Michelle A Chui, Linda Cappellini, John D Musil, Dennis J McCallian
The primary purpose of this six-week survey study of women currently taking compounded bioidentical hormone replacement therapy was to determine if compounded bioidentical hormone replacement therapy relieves symptoms of menopause and is well tolerated. The secondary purpose of this study was to compare the symptom relief and tolerability of compounded bioidentical hormone replacement therapy to previously used commercially available products. All strengths and dosage forms of bi-estrogen and tri-estrogen were included, whether used alone or in combination with progesterone, dehydroepiandrosterone or testosterone...
July 2004: International Journal of Pharmaceutical Compounding
Kenna Stephenson, Pierre F Neuenschwander, Anna K Kurdowska
Menopause impacts 25 million women world wide each year, and the World Health Organization estimates 1.2 billion women will be postmenopausal by 2030. Menopause has been associated with symptoms of hot flashes, night sweats, dysphoric mood, sleep disturbance, and conditions of cardiovascular disease, depression, osteoporosis, osteoarthritis, depression, dementia, and frailty. Conventional hormone replacement therapy results in increased thrombotic events, and an increased risk of breast cancer and dementia as evidenced in large prospective clinical trials including Heart and Estrogen/Progestin Replacement Study I and the Women's Health Initiative...
January 2013: International Journal of Pharmaceutical Compounding
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"